* Eloxx Pharmaceuticals Inc ELOX.OQ reported a quarterly
adjusted loss of 14 cents per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for a loss of 12 cents per share.
* Reported revenue was zero; analysts expected zero.
* Eloxx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 14 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Eloxx Pharmaceuticals Inc shares had fallen by 19.0% this
quarter.
* The company reported a quarterly loss of $12.09 million.
* Wall Street's median 12-month price target for Eloxx
Pharmaceuticals Inc is $3.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
This summary was machine generated March 31 at 12:11 p.m. All
figures in US dollars unless otherwise stated